Turkey real-life data: demographic features, treatment results and effects of comorbidities in chronic myeloid leukemia.
chronic myeloid leukemia
co-medication use
comorbidity
cytogenetic response
hematologic response
molecular response
survival
tyrosine kinase inhibitors
Journal
International journal of hematologic oncology
ISSN: 2045-1393
Titre abrégé: Int J Hematol Oncol
Pays: England
ID NLM: 101600758
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
21
05
2021
accepted:
09
06
2022
entrez:
14
9
2022
pubmed:
15
9
2022
medline:
15
9
2022
Statut:
epublish
Résumé
This study aimed to identify patient characteristics, treatment patterns and outcomes and to evaluate the effects of presence of comorbidities at diagnosis in chronic phase (CP)-chronic myeloid leukemia (CML) patients in Turkey. Hospital records between 2005 and 2018 were retrospectively reviewed. Of 861 CP-CML patients included, 31% had at least one comorbidity at diagnosis. Sex, cardiovascular disease status at diagnosis and molecular (at least major) and cytogenetic (partial and complete) responses were the independent predictors of survival. The response rates of CP-CML patients to the tyrosine kinase inhibitors were satisfactory. In addition to tolerability and side effect profiles of drugs, comorbidity status of patients should also be considered in treatment choice in CML patients. This study aimed to identify patient characteristics, treatment patterns and outcomes and to evaluate the effects of presence of comorbidities at diagnosis in chronic phase (CP)-chronic myeloid leukemia (CML) patients in Turkey. Hospital records of patients between 2005 and 2018 were retrospectively reviewed. Of the included 861 CP-CML patients, 31% had at least one comorbidity at diagnosis. The survival of the patients was affected by sex, cardiovascular disease status at diagnosis, and molecular (at least major) and cytogenetic (partial and complete) responses. The response rates of CP-CML patients to the tyrosine kinase inhibitors were satisfactory. In addition to tolerability and side effect profiles of drugs, comorbidity status of patients should also be considered in treatment choice in CML patients.
Autres résumés
Type: plain-language-summary
(eng)
This study aimed to identify patient characteristics, treatment patterns and outcomes and to evaluate the effects of presence of comorbidities at diagnosis in chronic phase (CP)-chronic myeloid leukemia (CML) patients in Turkey. Hospital records of patients between 2005 and 2018 were retrospectively reviewed. Of the included 861 CP-CML patients, 31% had at least one comorbidity at diagnosis. The survival of the patients was affected by sex, cardiovascular disease status at diagnosis, and molecular (at least major) and cytogenetic (partial and complete) responses. The response rates of CP-CML patients to the tyrosine kinase inhibitors were satisfactory. In addition to tolerability and side effect profiles of drugs, comorbidity status of patients should also be considered in treatment choice in CML patients.
Identifiants
pubmed: 36101779
doi: 10.2217/ijh-2021-0008
pmc: PMC9453544
doi:
Types de publication
Journal Article
Langues
eng
Pagination
IJH40Informations de copyright
© 2022 Guray Saydam.
Références
Ther Adv Hematol. 2018 Mar;9(3):65-78
pubmed: 29531660
N Engl J Med. 2006 Dec 7;355(23):2408-17
pubmed: 17151364
Curr Hematol Malig Rep. 2018 Jun;13(3):202-211
pubmed: 29687320
Acta Haematol. 2019;142(4):197-207
pubmed: 31163431
Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):161-167
pubmed: 30504305
Br J Haematol. 2016 Apr;173(1):114-26
pubmed: 26846160
Leuk Lymphoma. 2020 Apr;61(4):776-787
pubmed: 31739705
Leukemia. 2015 Jun;29(6):1336-43
pubmed: 25783795
Memo. 2016;9(4):157-162
pubmed: 28058062
Med Oncol. 2018 Sep 7;35(11):142
pubmed: 30194496
Am J Hematol. 2014 Jul;89(7):732-42
pubmed: 24711212
Ann Hematol. 2015 Apr;94 Suppl 2:S241-7
pubmed: 25814090
Clin Lymphoma Myeloma Leuk. 2015 Dec;15(12):797-802
pubmed: 26603185
Expert Rev Hematol. 2016 Oct;9(10):919-21
pubmed: 27606433
Leuk Lymphoma. 2020 Jan;61(1):98-107
pubmed: 31409168
Expert Rev Hematol. 2013 Oct;6(5):563-74
pubmed: 24083631
J Clin Oncol. 2018 Jan 20;36(3):231-237
pubmed: 29091516
Leukemia. 2020 Apr;34(4):966-984
pubmed: 32127639
Turk J Haematol. 2013 Dec;30(4):351-8
pubmed: 24385824
Clin Drug Investig. 2018 Sep;38(9):837-844
pubmed: 30043130
Int J Hematol. 2020 Mar;111(3):401-408
pubmed: 31894533
Med Oncol. 2018 Feb 13;35(3):38
pubmed: 29442179
Intern Med J. 2018 Feb;48 Suppl 2:5-13
pubmed: 29388307
Blood. 2015 Jul 2;126(1):42-9
pubmed: 25918346
Indian J Hematol Blood Transfus. 2019 Jan;35(1):37-42
pubmed: 30828146
Ann Hematol. 2016 Jan;95(2):211-9
pubmed: 26546359
Blood. 2013 Aug 8;122(6):872-84
pubmed: 23803709
Blood Rev. 2018 Jul;32(4):289-299
pubmed: 29454474
Eur J Intern Med. 2014 Jan;25(1):63-6
pubmed: 24309387
Oncotarget. 2018 Feb 12;9(18):14219-14227
pubmed: 29581839
Turk J Med Sci. 2019 Feb 11;49(1):1-10
pubmed: 30761815
Blood Rev. 2014 Sep;28(5):179-87
pubmed: 24984571
Ann Hematol. 2018 Apr;97(4):597-604
pubmed: 29305630
Leukemia. 2020 Aug;34(8):2125-2137
pubmed: 32572189
Int J Hematol. 2019 Apr;109(4):426-439
pubmed: 30762219
Daru. 2020 Jun;28(1):371-385
pubmed: 31900888
Ann Hematol. 2015 Apr;94 Suppl 2:S227-39
pubmed: 25814089
Curr Oncol Rep. 2018 Feb 28;20(2):12
pubmed: 29492683
Leuk Lymphoma. 2018 Jul;59(7):1523-1538
pubmed: 28972424
Acta Haematol. 2020;143(3):204-216
pubmed: 31514197
J Natl Compr Canc Netw. 2018 Sep;16(9):1108-1135
pubmed: 30181422
Leuk Res. 2017 Apr;55:65-78
pubmed: 28135648
Leukemia. 2017 Mar;31(3):593-601
pubmed: 27568522
Am J Hematol. 2019 Jan;94(1):46-54
pubmed: 30290003
Am J Hematol. 2012 Nov;87(11):1037-45
pubmed: 23090888
Am J Hematol. 2017 Nov;92(11):1214-1223
pubmed: 28815757